

REMARKS

Favorable reconsideration is respectfully requested in view of the forgoing amendments and following remarks.

Claims 1, 3-5 and 10-30 are pending.

Claims 12-13 and 25-26 have been amended to specify that the antibody is a monoclonal antibody.

The rejection of these claims under 35 USC 103 is deemed to be overcome in view of the submitted.

Claims 18 and 19 have been amended to change the term "comprising" to "consisting of".

The rejection of these claims as being substantial duplicates of 1 and 3 is deemed to be overcome in view of this amendment.

In view of the forgoing comments it is believed that each ground of rejection has been overcome, and that the application is now in condition for allowance. Accordingly, such allowance is solicited.

Respectfully submitted,

Kenichi ARAI et al.

ACCOOUNT NO. 23-0975
FEES FOR THIS PAPER TO DEPOSIT
TO CHARGE ANY DEFICIENCY IN THE
THE COMMISSIONER IS AUTHORIZED
By: Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/tg
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
December 10, 2003